Reports Q2 revenue $12.27B, consensus $11.38B. “We are making good progress rewiring the company for long-term growth. In the second quarter, we delivered strong results across our Growth Portfolio, continued to optimize our cost structure, and added to our innovative pipeline with strategic partnerships,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers (BMY) Squibb. “In the back half of the year, we’re focused on advancing transformational medicines and delivering on our Growth Portfolio and important pipeline opportunities to shape our growth trajectory.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Options Volatility and Implied Earnings Moves Today, July 31, 2025
- Notable companies reporting before tomorrow’s open
- Bristol-Myers Squibb’s Promising Phase 3 Study on KarXT for Bipolar-I Disorder
- Bristol-Myers Squibb’s New Study on Deucravacitinib: A Potential Game-Changer for Adolescent Psoriasis
- Bristol Myers Squibb put volume heavy and directionally bearish